Genetic biomarkers for migraine

Headache

Volumn 46, Issue 7, 2006, Pages 1059-1068

  De Vries, Boukje ^a   Haan, Joost ^a,b   Frants, Rune R ^a   Van Den Maagdenberg, Arn M J M ^a   Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNLAND HOSPITAL   (Netherlands)

Author keywords

ATP1A2; CACNA1A; FHM; Genetic biomarkers; Migraine; SCN1A

Indexed keywords

BIOLOGICAL MARKER;

DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE MUTATION; GENETIC LINKAGE; GENETIC VARIABILITY; GENETICS; HUMAN; MEASUREMENT; MIGRAINE; MIGRAINE WITH AURA; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT RESPONSE;

CALCIUM CHANNELS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIGRAINE DISORDERS; MUTATION; NA(+)-K(+)-EXCHANGING ATPASE; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; SODIUM CHANNELS; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 33745621579     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00499.x     Document Type: Review

References (90)

1. Ferrari MD. Migraine. Lancet. 1998;351:1043-1051.
2. Headache classification subcommittee of the international headache society. The International Classification of Headache Disorders, 2nd edn. Cephalalgia 2004;24:1-160.
3. Russell MB, Rasmussen BK, Thornvaldesen P, et al. Prevalence and sex ratio of the subtypes of migraine. Int J Epidemiol. 1995;24:612-618.
4. Bille B. A 40-year follow-up of school children with migraine. Cephalalgia. 1997;17:488-491.
5. Pietrobon D. Migraine: New molecular mechanisms. Neuroscientist. 2005;11:373-386.
6. Svensson DA, Larsson B, Waldenlind E, et al. Shared rearing environment in migraine: Results from twins reared apart and twins reared together. Headache. 2003;43:235-244.
7. Mulder EJ, Van Baal C, Gaist D, et al. Genetic and environmental influences on migraine: A twin study across six countries. Twin Res. 2003;6:422-431.
8. Cologno D, De Pascale A, Manzoni GC. Familial occurrence of migraine with aura in population-based study. Headache. 2003;43:231-234.
9. Noble-Topham SE, Cader MZ, Dyment DA, et al. Genetic loading in familial migraine with aura. J Neurol Neurosurg Psychiatr. 2003;74:1128-1130.
10. Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Curr Opin Neurol. 2005;18:698-705.
11. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: Proof of efficacy, utilization and cost. Cephalalgia. 1997;17:73-80.
12. Ducros A, Dernier C, Joutal A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med. 2001;354:17-24.
13. Terwindt G, Ophoff RA, Haan J, et al. Familial hemiplegic migraine: A clinical comparison of families linked and unlinked to chromosome 19. Cephalalgia. 1996;16:153-155.
14. Terwindt GM, Ophoff RA, Haan J, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology. 1998;50:1105-1110.
15. Kors EE, Terwindt GM, Vermeulen FL, et al. Delayed cerebral edema and fatal coma after minor head trauma: Role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol. 2001;49:753-760.
16. Del Zompo M, Cherchi A, Palmas MA, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998;51:781-786.
17. Haan J, Kors EE, Van den Maagdenberg AM, et al. Toward a molecular genetic classification of familial hemiplegic migraine. Curr Pain Headache Rep. 2004;8:238-243.
18. 2+ channel gene CACNL1A4. Cell. 1996;87:543-552.
19. Kors EE, Haan J, Giffi NJ, Pazdera L, et al. Expanding the phenotypic spectrum of the CACNA1A gene T666M mutation. A description of 5 families with familial hemiplegic migraine. Arch Neurol. 2003;60:684-688.
20. Kors EE, Melberg A, Vanmolkot KR, et al. Childhood epilepsy, familial hemiplegic migraine, cerebellar ataxia, and a new CACNA1A mutation. Neurology. 2004;63:1136-1137.
21. + pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet. 2003;33:192-196.
22. +-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol. 2003;54:360-366.
23. Swoboda KJ, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. Ann Neurol. 2004;55:884-887.
24. Ambriosini A, D'Onofrio, Grieco GS, et al. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. Neurology. 2005;13:1826-1828.
25. Todt U, Dichgans M, Jurkat-Rott K. Rare missense variants in ATP1A2 in families with clustering of common forms of migraine. Hum Mutat. 2005;26:315-321.
26. Dichgans M, Freilinger T, Eckstein G. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet. 2005;336:371-377.
27. Steinlein OK. Genetic mechanisms that underlie epilepsy. Nat Rev Neurosci. 2004;5:400-408.
28. Pietrobon D. Migraine: New molecular mechanisms. Neuroscientist. 2005;11:373-386.
29. Segall L, Scanzano R, Kaunisto MA, et al. Kinetic alterations due to a missense mutation in the Na,K-ATPase alpha 2 subunit cause familial hemiplegic migraine type 2. J Biol Chem. 2004;279:43692-43696.
30. Segall L, Mezzetti A, Scanzano R, et al. Alterations in the alpha2 isoform of Na,K-ATPase associated with familial hemiplegic migraine type 2. Proc Natl Acad Sci USA. 2005;102:11106-11111.
31. Koenderink JB, Zifarelli G, Oiu LY, et al. Na,K-ATPase mutations in familial hemiplegic migraine lead to functional inactivation. Biophys Acta. 2005;1669:61-68.
32. Jen JC, Wan J, Palos T, et al. Mutation in the glutamate transporter EAAT1 causes episodic atraxia, hemiplegia, and seizures. Neurology. 2005;65:529-534.
33. Vahedi K, Dernier C, Ducros, et al. CACNA1A gene de novo mutation causing hemiplegic migraine, coma, and cerebellar atrophy. Neurology. 2000;55:1040-1042.
34. Terwindt G, Kors E, Haan J, et al. Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine. Arch Neurol. 2002;59:1016-1018.
35. Ducros A, Dernier C, Joutel A, et al. Recurrence of the T666M calcium channel CACNA1A gene mutation in familial hemiplegic migraine with progressive cerebellar ataxia. Am J Hum Genet. 1999;64:89-98.
36. +-ATPase variants. Neurology. 2004;62:1857-1861.
37. Hovatta I, Kallela M, Farkkila M, et al. Familial migraine: Exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine of 19p. Genomics. 1994;23:707-709.
38. Noble-Topham SE, Dyment DA, Cader MZ, et al. Migraine with aura is not linked to the FHM gene CACNA1A or the chromosomal region, 19p13. Neurology. 2002;59:1099-1101.
39. Nyholt DR, Lea RA, Goadsby PJ, et al. Familial typical migraine: Linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology. 1998;50:1428-1432.
40. Lea RA, Curtain RP, Hutchins RP, et al. Investigation of the CACNA1A gene as a candidate for typical migraine susceptibility. Am J Med Genet. 2001;105:707-712.
41. May A, Ophoff RA, Terwindt GM, et al. Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Hum Genet. 1995;96:604-608.
42. Terwindt GM, Ophoff RA, van Eijk R, et al. Involvement of the P/Q type calcium channel α1A-subunit (CACNA1A) gene region on 19p13 in migraine with and without aura. Neurology. 2001;56:1028-1032.
43. Curtain RP, Lea RA, Tajouri L, et al. Analysis of chromosome 1 microsatellite markers and the FHM2-ATP1A2 gene mutations in migraine pedigrees. Neurol Res. 2005;27:647-652.
44. Jen JX, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Arch Neurol. 2004;61:926-928.
45. Wessman M, Kallela M, Kaunisto, et al. A susceptibility locus for migraine with aura, on chromosome 4q24. Am J Hum Genet. 2002;70:652-662.
46. Bjornsson A, Gudmundsson G, Gudfinnsson E, et al. Localization of a gene for migraine without aura to chromosome 4q21. Am J Hum Genet. 2003;73:986-993.
47. Carlsson A, Forsgren L, Nylander PO, et al. Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology. 2002;59:1804-1807.
48. Nyholt DR, Morley KI, Ferreira MA, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet. 2005;77:500-512.
49. Rindskoff D, Rindskopf W. The value of latent class analysis in medical diagnosis. Med Stat. 1986;5:12-27.
50. Lea RA, Nyholt DR, Curtain RP. A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine. Neurogenetics. 2005;6:67-72.
51. Cader ZM, Noble-Topham S, Dyment DA, et al. Significant linkage to migraine with aura on chromosome 11q24. Hum Mol Genet. 2003;12:2511-2517.
52. Soragna D, Vettori A, Carraro G, et al. A locus for migraine without aura maps on chromosome 14q21.2-q22.3. Am J Hum Genet. 2003;72:161-167.
53. Nyholt DR, Dawkins JL, Brimage PJ, et al. Evidence for an X-linked genetic component in familial typical migraine. Hum Mol Genet. 1998;7:459-463.
54. Nyholt DR, Curtain BP, Griffiths LR. Familial typical migraine: Significant linkage and localization of a gene to Xq24-28. Hum Genet. 2000;107:18-23.
55. Russo L, Mariotti P, Sangiorgi E, et al. A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am J Hum Genet. 2005;76:327-333.
56. Ferrari MD, Haan J, Palotie A. Genetics of migraine. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006;28:251-269.
57. Kowa H, Yasui K, Takeshima T, et al. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000;96:762-764.
58. Kara I, Sazci A, Ergul E, et al. Association of the C677T and A1298C polymorphisms in the 5,10 methylenetetrahydrofolate reductase gene in patients with migraine risk. Brain Res Mol Brain Res. 2003;111:84-90.
59. Lea RA, Ovcaric M, Sundholm J, et al. The methylenetetrahydrofolate reductase gene variant C677T influences susceptibility to migraine with aura. BMC Med. 2004;12;2-3.
60. Oterino A, Valle N, Bravo Y, et al. MTHFR T677 homozygosis influences the presence of aura in migraineurs. Cephalalgia. 2004;24:491-494.
61. Scher AI, Terwindt GM, Verschuren WMM, et al. Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol. 2006;59:372-375.
62. Lea RA, Ovcaric M, Sundholm, et al. Genetic variants of angiotensin converting enzyme and methylenetetrahydrofolate reductase may act in combination to increase migraine susceptibility. Brain Res Mol Brain Res. 2005;136:112-117.
63. Paterna S, Di Pasquale P, Dángelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000;43:133-136.
64. Kowa H, Fusayasa E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neuroscience. 2005;374:129-131.
65. Lin JJ, Wang PJ, Chen CH, et al. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta Neurol Taiwan. 2005;14:120-125.
66. Buchwalder A, Welch SK, Peroutka SJ. Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. Headache. 1996;36:254-258.
67. Mochi M, Cevoli S, Cortelli P, et al. A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta- hydroxylase genes. Neurol Sci. 2003;23:301-305.
68. Nyholt DR, Curtain RP, Gaffney PT, Brimage P, Goadsby PJ, Griffiths LR. Migraine association and linkage analyses of the human 5-hydroxytryptamine (5HT2A) receptor gene. Cephalalgia. 1996;16:463-467.
69. Juhasz G, Zsombok T, Laszik A, et al. Association analysis of 5-HTTLPR variants5-HT(2A) receptor gene 102T/C polymorphism and migraine. J Neurogenet. 2003;17:231-240.
70. Burnet PW, Harrison PJ, Goodwin GM, et al. Allelic variation in the serotonin 5-HT2C receptor gene and migraine. Neuroreport. 1997;18:2651-2653.
71. Johnson MP, Lea RA, Curtain RP, et al. An investigation of the 5-HT2C receptor gene as a migraine candidate gene. Am J Med Genet. 2003;117:86-89.
72. Maassen VanDenBrink A, Vergouwe MN, Ophoff RA, et al. Chromosomal localization of the 5-HT1F receptor gene: No evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet. 1998;77:415-420.
73. Kim WK, Kim HS, Kim WJ, et al. Serotonin transporter gene polymorphism and migraine in the Korean population. Headache. 2005;45:1056-1060.
74. Johnson MP, Griffiths LR. A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J Hum Genet. 2005;50:607-610.
75. Ogilvie AD, Russell MB, Dhall P, et al. Altered allelic distribution of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia. 1998;18:23-26.
76. Erdal E, Herken H, Yilmaz M, et al. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001;94:193-196.
77. Yilmaz M, Erdal ME, Herken H, et al. Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci. 2001;186:27-30.
78. Kotoni K, Shimomura T, Shimomura F, et al. A polymorphism in the serotonin transporter gene regulatory region and frequency of migraine attacks. Headache. 2002;42:893-895.
79. Borroni B, Brambilla C, Liberini P, et al. Functional serotonin 5-HTTLPR polymorphism is a risk factor for migraine with aura. J Headache Pain. 2005;6:182-184.
80. Marziniak M, M̈ossner R, Schmitt A, Lesch KP, Sommer C. A functional serotonin transporter gene polymorphism is associated with migraine with aura. Neurology 2005;64:157-159.
81. Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trail. Neurology. 2003;60:315-321.
82. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med. 2002; 23: 141-148.
83. Somerville BW, Herrmann WM. Migraine prophylaxis with Lisuride hydrogen maleate - a duble blind study of Lisuride versus placebo. Headache. 1978; 18:75-79.
84. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997;49:201-206.
85. Peroutka SJ, Price SC, Wilhoit TL, et al. Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med. 1998;4:14-21.
86. Dichgans M, Forderreuther S, Dieterich M, Pfaffenrath V, Gasser T. The D2 receptor Nco1 allele: Absence of allelic association with migraine with aura. Neurology. 1998;51:928.
87. Rebaudengo N, Rainero I, Parziale A, et al. Lack of interaction between a polymorphism in the dopamine D2 gene and the clinical features of migraine. Cephalalgia. 2004;24:503-507.
88. Maude S, Curtin J, Breen G, et al. The -141C Ins/Del polymorphism of the dopamine D2 receptor gene is not associated with either migraine or Parkinson's disease. Psychiatr Genet. 2001;11:49-52.
89. Montagna P, Pierangeli G, Cevoli S, et al. Pharmacogenetics of headache treatment. Neurol Sci. 2005;26:143-147.
90. Rogers, Lea RA, Griffiths LR. Molecular mechanisms of migraine: Prospects for pharmacogenomics. Am J Pharmacogenomics 2003;3:329-343.